SCHEMBL131041

SCHEMBL131041

C=CC[CH]O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23546 0.71
SCHEMBL702020 0.71
SCHEMBL571282 0.69
SCHEMBL571281 0.69
Ammonia Solution, Strong SCHEMBL7121772 0.67
SCHEMBL27751093 0.67
SCHEMBL18783524 0.67
SCHEMBL10458007 0.67
Water SCHEMBL27372388 0.67
SCHEMBL11655335 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4223823-A1 NOVEL POLYURETHANES HAVING PENDANT EPOXY GROUPS AND THERMOSETS THEREOF Covestro LLC (US) 2023-08-09 EP claimed
WO-2023114645-A1 NOVEL POLYURETHANES HAVING PENDANT EPOXY GROUPS AND THERMOSETS THEREOF COVESTRO LLC (US) 2023-06-22 WO claimed
EP-3254675-B1 DELAYED RELEASE, ORAL DOSAGE COMPOSITIONS THAT CONTAIN AMORPHOUS CDDO-ME REATA PHARMACEUTICALS INC (US) 2019-05-15 EP claimed
US-9155721-B2 Delayed release, oral dosage compositions that contain amorphous CDDO-Me REATA PHARMACEUTICALS, INC. (US) 2015-10-13 US claimed
US-20140235711-A1 DELAYED RELEASE, ORAL DOSAGE COMPOSITIONS THAT CONTAIN AMORPHOUS CDDO-ME REATA PHARMACEUTICALS, INC. (US) 2014-08-21 US claimed
EP-1490356-B1 (3Z)-3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS ALLERGAN INC (US) 2013-02-27 EP claimed
US-20120022156-A1 DELAYED RELEASE, ORAL DOSAGE COMPOSITIONS THAT CONTAIN AMORPHOUS CDDO-ME REATA PHARMACEUTICALS, INC. (US) 2012-01-26 US claimed
WO-2010093944-A2 DELAYED RELEASE, ORAL DOSAGE COMPOSITIONS THAT CONTAIN AMORPHOUS CDDO-ME REATA PHARMACEUTICALS, INC. (US) 2010-08-19 WO claimed
US-20090105292-A9 Glucocorticoid Receptor Modulator Compounds and Methods LIGAND PHARMACEUTICALS INCORPORATED (US) 2009-04-23 US claimed
US-20070281959-A1 Glucocorticoid receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED (US) 2007-12-06 US claimed
EP-1218358-A1 THERAPEUTIC QUINAZOLINE COMPOUNDS AstraZeneca AB (SE) 2002-07-03 EP claimed
US-6399603-B1 QUINAZOLINES; RETARDING APOPTOSIS IN CELLS; INHIBITING CLEAVAGE OF PROTEIN SUBSTRATES BY CASPASE-3; CHEMICAL AND HYDROLYTIC STABILITY ASTRAZENECA AB (SE) 2002-06-04 US claimed
EP-0586474-B1 PEPTIDE NUCLEIC ACIDS BUCHARDT OLE (DK) 2001-09-12 EP claimed
WO-2001021598-A1 THERAPEUTIC QUINAZOLINE COMPOUNDS ASTRAZENECA AB (SE) 2001-03-29 WO claimed
WO-1999039914-A1 INK RECEPTIVE SHEET MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1999-08-12 WO claimed
US-5068140-A Transparencies XEROX CORPORATION (US) 1991-11-26 US claimed
EP-0450480-A2 Somatostatin Analogues The Administrators of The Tulane Educational Fund (US) 1991-10-09 EP claimed
EP-0100200-B1 2-SUBSTITUTED 4-AMINO-6,7-DIMETHOXYQUINOLINES Pfizer Limited (GB) 1987-05-06 EP claimed
EP-0083960-B1 SPRAYABLE ACOUSTICAL COMPOSITION UNITED STATES GYPSUM COMPANY (US) 1985-11-27 EP claimed
EP-0100200-A1 2-Substituted 4-amino-6,7-dimethoxyquinolines Pfizer Limited (GB) 1984-02-08 EP claimed